Drug Price Personality: Are You Winning or Losing in Trump's 2026 MFN Deal?

# Drug Price Personality: Are You Winning or Losing in Trump's 2026 MFN Deal?

> **Quick answer:** There are four drug price personality types in 2026. The Bargain Hunter is already saving on MFN-covered brand-name drugs like Praluent at $225 via TrumpRx. The Waiting Game is on a branded drug not yet in a deal but likely to be covered soon. The Tariff Trap is caught between MFN savings and incoming July 31 pharma tariffs. The Unaffected is a generic drug user who is largely insulated from both programs.

The most consequential shift in US drug pricing in a generation happened in April 2026 — and most Americans don't know which side of it they're on. Trump's most favored nation (MFN) drug pricing program now covers 86% of the branded drug market, Praluent dropped from $537 to $225 overnight, and a 100% pharmaceutical import tariff kicks in July 31 for manufacturers who haven't signed deals. Depending on what medications you take, you are either winning big or walking into a price trap. Fizzty research shows that patients who proactively identify their drug price type before the July 31 deadline save significantly more than those who wait for their pharmacist to deliver a surprise.

## What Is Trump's Most Favored Nation Drug Pricing Program?

Most favored nation pricing means the US government — and through TrumpRx, individual patients — pays no more for a drug than the lowest price paid by any comparable developed nation. The reference countries include Canada, Germany, Japan, France, and the United Kingdom, all of which negotiate drug prices nationally through government bodies. The result is that those countries pay substantially less than Americans for identical drugs: typically three to five times less for the same branded product.

The MFN framework works through voluntary agreements. Pharmaceutical manufacturers who sign MFN deals with the White House receive exemptions from Section 232 pharmaceutical tariffs and agree to offer US patients the international reference price through TrumpRx.gov. By April 23, 2026, when Regeneron became the 17th company to sign, the program covered 86% of the branded drug market. Regeneron's PCSK9 inhibitor Praluent — used to treat familial hypercholesterolemia and cardiovascular disease — became the most visible example: a drug that cost $537 per month dropped to $225 at TrumpRx pricing, a 58% reduction.